Abstract
The review examines the clinical role of terbium isotopes in the context of their integration into modern routine practice in nuclear medicine. Low toxicity, combined with an optimal half-life and elimination time from the body, makes them very promising not only in the therapeutic sense, but also in the issue of diagnostic imaging of tumors. When performing PET /CT and SPECT/CT imaging with 152Tb and 155Tb isotopes on cancer patients, high diagnostic information values were obtained. It should be noted that in the context of 152Tb, the phase of clinical trials on patients has already been completed, according to the results of which this radionuclide has demonstrated its potential. SPECT with 155Tb provides excellent imaging performance in mammals, even with low levels of injected radioactivity, which makes it promising for use in humans. Key words: terbium, nuclear medicine, single-photon emission tomography, positron emission tomography
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
